Harmony Biosciences Raises $270m; Acquires US Rights To Narcolepsy Drug
Emerging US biotech Harmony Biosciences has secured $270m in financing to acquire a Phase III narcolepsy drug, which it expects to file with the FDA in 2018.
Emerging US biotech Harmony Biosciences has secured $270m in financing to acquire a Phase III narcolepsy drug, which it expects to file with the FDA in 2018.